Having noticed the immune-responsive phenotype of NSCLC with high SIRPG expression, we next hypothesized that NSCLC patients whose pre-treatment tumors with high SIRPG expression may show good response to PD-1 blockade. Here, SIRPG is linked to non-small cell lung carcinoma.